Salian Foundation, MedEthix, and I.E. Medica Bring Free Healthcare Services To Underserved Individuals in Cebu

Posted on 0 Comments

Salian Foundation, MedEthix, and I.E. Medica Bring Free Healthcare Services To Underserved Individuals in Cebu

CEBU, Philippines – The Salian Foundation, in partnership with I.E. Medica and MedEthix and in coordination with the University of Cebu Medical Center, held a medical mission last February 8, 2025, at Holy Family Parish, providing free consultations and diagnoses to underserved community members.

Beyond primary care, it offered specialized medical services, including eye checkups, pediatric care, orthopedic consultations, and cervical cancer screening. Salian Foundation also dispensed free medicines to beneficiaries based on doctors’ prescriptions.

MedEthix focused on enhancing women’s healthcare services, particularly in reproductive health. With its commitment to advancing women’s health solutions, MedEthix supported the mission’s cervical cancer screening efforts. By integrating the services of an onsite OBGYNE into the endeavor, the

 initiative helped empower women with the knowledge and medical assistance necessary to take charge of their health.

 initiative helped empower women with the knowledge and medical assistance necessary to take charge of their health.

 

Meanwhile, I.E. Medica’s mission to provide care every step of the way in the patient journey against cancer plays a crucial role in expanding the m

edical mission’s scope by supporting oncology-related services. Through its strategic partnerships, I.E. Medica helped provide access to an essential detection effort and patient education on managing cervical c

ancer. This initiative aimed to address the burden of the disease among 

underserved individuals, ensuring that early intervention and proper care were within reach for those who needed it most.

 

This approach allowed Salian Foundation to provide systematic, high-quality medical assistance to this community in Cebu. Salian Foundation Inc is set to expand its outreach with more medical missions, focusing on remote communities. These efforts reinforce the foundation’s commitment to bringing quality healthcare to those who need it most.

Molnupiravir arrives in the Philippines, the first in Southeast Asia, through MedEthix, JackPharma

Posted on

Molnupiravir arrives in the Philippines, the first in Southeast Asia, through MedEthix, JackPharma

The first shipment of Molnupiravir, an oral anti-viral treatment for mild COVID-19, arrived in the country through a partnership between MedEthix, one of the country’s major pharmaceutical importers and distributors, and JackPharma, a pharmaceutical distribution company. MedEthix is a member of the Ayala Healthcare Holdings, Inc. (AC Health), the healthcare arm of the Ayala Group.

Present to receive the first shipment of Molnupiravir at the PAIR Cargo Terminal, Pasay City were Monaliza B. Salian, MedEthix Co-founder, President, and Chief Executive Officer; Meny Hernandez, JackPharma Inc. President; Ma. Victoria P. Sugapong, MedEthix Chief Operating Officer; Paolo F. Borromeo, AC Health President and CEO; Ruby P. Chiong AC Health Chief Finance Officer; Dr. Rizzy A. Alejandro, AC Health Chief Public Health Officer; Michael P. Narvaez, People’s Air Cargo & Warehousing Co. Inc. Chief Operating Officer and Norsalem Raymond M. Mama-o, OIC of PAIR CARGO Assessment Composite Division. The event was facilitated by QuickFlo Forwarders, Inc., the customs brokerage partner of MedEthix and JackPharma.

Molnupiravir, brand name Molnaflu, is being imported into the country via Compassionate Special Permits (CSPs) issued by the Philippine FDA to several hospitals in the country, including AC Health’s QualiMed hospitals, as well as 30 other hospitals all over the country. The newly-arrived Molnupiravir treatment courses are supplied by Aurobindo Pharma, an Indian pharma manufacturer licensed by Merck to supply this drug to low and middle-income countries. The Philippines is the first country in Southeast Asia to receive their supply of Molnupiravir and will be available to the public as of today.

The drug, developed by Emory University and Merck, was shown in clinical trials to reduce the risk of hospitalization and death by 50% for patients with mild COVID-19. Molnupiravir could potentially help reduce the burden of COVID-19 to the healthcare system by providing a much-needed option for outpatient treatment to prevent progression to severe disease and death.

Under a CSP, patients diagnosed with mild COVID-19 can be prescribed Molnupiravir, and can avail of the drug from a hospital granted a CSP. Molnupiravir comes in a 200mg capsule with a recommended regimen of 800mg (4 capsules) to be taken twice a day for 5 days or as prescribed by a physician. It will be available in a bottle of 40 capsules to cover the entire treatment regimen. “We are delighted that MedEthix and JackPharma have made it possible to bring Molnupiravir into the country. This drug is a game-changer, and we look forward to offering this life-saving medicine to our patients at QualiMed. Moreover, we are extremely proud that, through the efforts of MedEthix and JackPharma, Molnupiravir will be available nationwide for our countrymen at an affordable price. This is very much in line with the commitment of AC Health and the Ayala Group to support the country’s COVID-19 response efforts,” said Paolo Borromeo, AC Health President & CEO.

Earlier in the pandemic, AC Health, with the help of its partners, built and capacitated 8 RT-PCR labs for COVID-19 testing, and converted its 4 QualiMed hospitals in Sta Rosa, Laguna; San Jose Del Monte, Bulacan; Tanauan, Batangas, and Iloilo City into COVID-19 referral hospitals. More recently, AC Health has become one of the largest Healthcare Service Providers of COVID-19 vaccines, and has administered close to 600,000 doses in over 25 vaccination sites across the country.

MedEthix, JackPharma to Bring Molnupiravir COVID-19 Treatment Pill to PH

Posted on

MedEthix, JackPharma to Bring Molnupiravir COVID-19 Treatment Pill to PH

COVID-19 cases in the country exceeded 20,000 cases per day in the past weeks as reported by the Department of Health (DOH). Although the number has since been on the decline and the majority of these cases are mild amid vaccination efforts, concerns about health and safety and uncertainty about the future are still palpable.

MedEthix, a wholly owned Filipino company importing and distributing a wide range of healthcare products established in 2009, is bringing to the country Molnupiravir, the new oral antiviral pill for mild COVID-19 cases. MedEthix is the first importer in the country to secure, on behalf of the first four grantees, the Compassionate Special Permit (CSP) for Molnupiravir.

Meanwhile, JackPharma Inc., a pharmaceutical company founded in June 2015, will distribute the new drug to frontliners and other healthcare professionals.

Molnupiravir, developed by Emory University and MSD (Merck), will allow patients with mild COVID-19 symptoms to be treated early in an outpatient setting. MSD has inked voluntary in-licensing deals with Indian pharma manufacturers to supply Molnupiravir to low and middle-income countries, including the Philippines.

As the first local importer to be granted CSP as early as September, MedEthix is likely to be the first to distribute the new drug to Filipinos through its partnerships with hospitals.

“Living our principle to heal always and in all ways, we at MedEthix are actively looking for ways to help Filipinos have a better chance at fighting the virus. So, we took the chance to apply for a CSP once MSD announced promising initial clinical results for Molnupiravir. We are honored to bring this treatment drug to the country as early as November and we assure Filipinos that we are going to offer the same level of quality as with our other products and services,” shares Monaliza Salian, MedEthix co-founder, president and chief executive officer.

Molnupiravir: What we know so far

Molnupiravir works by introducing copying errors during viral RNA replication. The drug enters the COVID-19 virus and alters it to become harmless. Even if the virus replicates, it is no longer deadly.

Results of clinical trials sponsored by MSD licensee Aurobindo Pharma in India showed that 81 percent of the 1,200 mild cases taking Molnupiravir had negative RT-PCR results on the fifth day of treatment. This is compared to 17 percent of cases given only Standard of Care. All the patients included in the study were treated at home, which lessens the stress of finding a hospital that can accommodate COVID-19 patients.

Molnupiravir comes in a 200mg capsule with a recommended regimen of 800mg to be taken twice daily for 5 days or as prescribed by a physician. It comes in a bottle of 40 capsules, which is the entire dose.

“JackPharma is pleased to be part of the alliance as the first to bring Molnupiravir to our healthcare frontliners and the Filipino patients. With Molnupiravir, the treatment of COVID-19 has shifted — patients can now be treated at home without the need to go to the hospital,” shares Meny Hernandez, JackPharma president.

MedEthix and JackPharma will further discuss how Molnupiravir works in the treatment of mild COVID-19 during meetings and webinars with healthcare frontliners scheduled in November.

For any queries, please contact MedEthix at info@medethix.com.ph or +632 7373-7777, +63-969 0170380 and +63-945 4559829, and JackPharma at info@jackpharma.com or +63-917 1685225.

AC Health invests in pharma supply chain through IE Medica and MedEthix

Posted on

AC Health invests in pharma supply chain through IE Medica and MedEthix

Ayala Healthcare Holdings, Inc. (AC Health) expanded its pharma portfolio with new investments into IE Medica, one of the major importers of pharmaceutical productsin the country, and MedEthix, affiliated distribution company.

The agreement, in which AC Health acquired minority stakes in both companies, wassigned on November 12, 2019 between IE Medica’s principals, Vasant and MonalizaSalian, and the AC Health leadership team led by Fernando Zobel de Ayala, Chairmanof the Board, Paolo Borromeo, President and CEO, and Atty. Josette Abarca,Chief Finance Officer.

IE Medica and MedEthix were founded by Vasant and Monaliza Salian in 2006 and2009, respectively, with the goal of importing and distributing a wide range of medicines,including generics and innovative drug delivery systems. Since then, the company hasgrown to become a key player in the pharmaceutical industry, and has establishedits presence across various therapeutic areas.

“Our investment into IE Medica and MedEthix fits well with AC Health’s overall vision to improve healthcare. The Salians have built an impressive platform, and we are happy they share in our vision to bring quality, affordable medicines to more Filipinos,”said Zobel de Ayala.

“We are honored to be part of the AC Health family, and we believe that this will usher inopportunities for synergy and growth,” said IE Medica founder, Vasant Salian.

The investments in IE Medica and MedEthix will allow AC Health to vertically integrate its pharmaceutical portfolio, and further strengthen the supply chain for its network ofover 800 Generika pharmacies, and 70 FamilyDOC primary care clinics. In the future,this partnership will also allow AC Health to offer more affordable medicines at its cancer hospital, which will open in 2022.

“We are excited by this unique opportunity to bring together our individual strengths. By combining the expertise of IE Medica and MedEthix in sourcing and distribution, with the reach and scale of our AC Health portfolio, we will be able to bring in a wider range of affordable medicines and improve access across our network,” added AC Health President & CEO, Paolo Borromeo.

The investment is timely given the forthcoming signing of the Executive Order forMaximum Drug Retail Price (MDRP). Other regulatory changes are expected to be implemented in line with the Universal Health Care Act and the National Cancer Control Act.

1 2

Partner with Us

Please enable JavaScript in your browser to complete this form.

Become Our Distribution Partner

Please fill out the form below and we’ll be in touch as soon as possible.

Partner with Us

Please enable JavaScript in your browser to complete this form.

Become Our Manufacturing Partner

Please fill out the form below and we’ll be in touch as soon as possible.

Product Inquiry

Please enable JavaScript in your browser to complete this form.
Name
Click or drag files to this area to upload. You can upload up to 5 files.

Terms and Conditions